What is claimed is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH-, -N(C_1-C_6)alkyl-, or -N-(O-C_1-C_6 alkyl)-;

R_1 is -halo, -CH_3, -NO_2, -CN, -OH, -OCH_3, -NH_2, C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_2 is independently:

(a) -halo, -OH, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

2. The compound of claim 1, wherein:

n is 0;

m is 0; and

R_4 is phenyl.

3. The compound of claim 2, wherein the R_4 phenyl is unsubstituted.

4. The compound of claim 2, wherein the R_4 phenyl is substituted at the 4-position.

5. The compound of claim 4, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

6. The compound of claim 5, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

7. The compound of claim 5, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

8. The compound of claim 4, wherein the R_4 phenyl is substituted with a -CF_3 group.

9. The compound of claim 4, wherein the R_4 phenyl is substituted with a -OCF_3 group.

10. The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_4 is phenyl.

11. The compound of claim 10, wherein the R_4 phenyl is unsubstituted.

12. The compound of claim 10, wherein the R_4 phenyl is substituted at the 4-position.

13. The compound of claim 12, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

14. The compound of claim 13, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

15. The compound of claim 13, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

16. The compound of claim 12, wherein the phenyl is substituted with a -CF_3 group.

17. The compound of claim 12, wherein the phenyl is substituted with a -OCF_3 group.

18. The compound of claim 1, wherein A is -NH-.

19. The compound of claim 1, wherein A is -N(C_1-C_6)alkyl-.

20. The compound of claim 1, wherein A is -N-(O-C_1-C_6 alkyl)-.

21. A compound of formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

A is -N(O-C_1-C_6 alkyl)-, -CH_2-, -CH_2CH_2-, or -CH=CH-;

R_1 is -halo, -CH_3, -NO_2, -CN, -OH, -OCH_3, -NH_2, C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_2 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -$CH{=}NR_7$, -NR_7OH, -OR_7, -COR_7, -$C(O)OR_7$, -$OC(O)R_7$, -$OC(O)OR_7$, -SR_7, -$S(O)R_7$, or -$S(O)_2R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -$C(halo)_3$, -$CH(halo)_2$, -$CH_2(halo)$, -CN, -OH, -halo, -N_3, -NO_2, -$N(R_7)_2$, -$CH{=}NR_7$, -NR_7OH, -OR_7, -COR_7, -$C(O)OR_7$, -$OC(O)R_7$, -$OC(O)OR_7$, -SR_7, -$S(O)R_7$, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -$C(halo)_3$, -$CH(halo)_2$, or $CH_2(halo)$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

22. The compound of claim 21, wherein:

n is 0;

m is 0; and

R_4 is phenyl.

23. The compound of claim 22, wherein the R_4 phenyl is unsubstituted.

24. The compound of claim 22, wherein the R_4 phenyl is substituted at the 4-position.

25. The compound of claim 24, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

26. The compound of claim 25, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

27. The compound of claim 25, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

28. The compound of claim 24, wherein the R_4 phenyl is substituted with a -CF_3 group.

29. The compound of claim 24, wherein the R_4 phenyl is substituted with a -OCF_3 group.

30. The compound of claim 21, wherein:
n is 0;
m is 1;
R_3 is methyl; and
R_4 is phenyl.

31. The compound of claim 30, wherein the R_4 phenyl is unsubstituted.

32. The compound of claim 30, wherein the R_4 phenyl is substituted at the 4-position.

33. The compound of claim 32, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

34. The compound of claim 33, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

35. The compound of claim 33, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

36. The compound of claim 32, wherein the R_4 phenyl is substituted with a -CF_3 group.

37. The compound of claim 32, wherein the R_4 phenyl is substituted with a -OCF_3 group.

38. The compound of claim 21, wherein A is -N(O-C_1-C_6 alkyl)-.

39. The compound of claim 21, wherein A is -CH_2-.

40. The compound of claim 21, wherein A is -CH_2CH_2-.

41. The compound of claim 21, wherein A is -CH=CH-.

42. A compound of formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH- or -N(C_1-C_6 alkyl)-;

R_1 is -halo, -CH_3, -NO_2, -CN, -OH, -OCH_3, -NH_2, C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_2 is independently:

(a) -halo,-OH, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-

membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -N(R_7)$_2$, -CH=NR_7, -NR_7OH, -OR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -S(O)$_2$$R_7$;

each R_6 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_7)$_2$, -CH=NR_7, -NR_7OH, -OR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -S(O)$_2$$R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

43. The compound of claim 42, wherein:

n is 0;

m is 0; and

R_4 is phenyl.

44. The compound of claim 43, wherein the R_4 phenyl is unsubstituted.

45. The compound of claim 43, wherein the R_4 phenyl is substituted at the 4-position.

46. The compound of claim 45, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

47. The compound of claim 46, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

48. The compound of claim 46, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

49. The compound of claim 45, wherein the R_4 phenyl is substituted with a -CF_3 group.

50. The compound of claim 45, wherein the R_4 phenyl is substituted with a -OCF_3 group.

51. The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_4 is phenyl.

52. The compound of claim 51, wherein the R_4 phenyl is unsubstituted.

53. The compound of claim 51, wherein the R_4 phenyl is substituted at the 4-position.

54. The compound of claim 53, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

55. The compound of claim 54, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

56. The compound of claim 54, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

57. The compound of claim 53, wherein the R_4 phenyl is substituted with a -CF_3 group.

58. The compound of claim 53, wherein the R_4 phenyl is substituted with a -OCF_3 group.

59. The compound of claim 42, wherein A is -NH-.

60. The compound of claim 42, wherein A is -N(C_1-C_6 alkyl)-.

61. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

62. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

63. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42 and a pharmaceutically acceptable carrier or excipient.

64. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

65. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

66. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

67. A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

68. A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

69. A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

70. A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

71. A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

72. A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

73. A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

74. A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

75. A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

76. A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

77. A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

78. A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

79. A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

80. A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

81. A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

82. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

83. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 21.

84. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 42.

85. A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

86. A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

87. A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 42 and a pharmaceutically acceptable carrier or excipient.

88. A compound of formula formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

Ar_2 is



R_1 is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $C(halo)_3$, $-CH(halo)_2$, or
$-CH_2(halo)$;

each R_2 is independently:

(a) -halo,-CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -$(C_1$-$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -$(C_2$-$C_6)$alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -$(C_1$–$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -$(C_2$-$C_6)$alkynyl, -$(C_3$-$C_8)$cycloalkyl, -$(C_5$–$C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -$(C_1$-$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -$(C_2$-$C_6)$alkynyl, -$(C_3$-$C_8)$cycloalkyl, -$(C_5$-$C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo);

each R_8 is independently -$(C_1$–$C_6)$alkyl, -$(C_2$–$C_6)$alkenyl, -$(C_2$–$C_6)$alkynyl, -$(C_3$–$C_8)$cycloalkyl, -$(C_5$–$C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or CH_2(halo);

each R_9 is independently -$(C_1$–$C_6)$alkyl, -$(C_2$–$C_6)$alkenyl, -$(C_2$–$C_6)$alkynyl, -$(C_3$-$C_8)$cycloalkyl, -$(C_5$–$C_8)$cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, or CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_{11} is independently -CN, -OH, -$(C_1$–$C_6)$alkyl, -$(C_2$–$C_6)$alkenyl, -$(C_2$–$C_6)$alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

89. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87 and a pharmaceutically acceptable carrier or excipient.

90. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87.

91. A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87.

92. A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87.

93. A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87.

94. A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87.
B65

95. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 87.

96. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 87.

97. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 87.

98. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 87.

99. A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 87 and a pharmaceutically acceptable carrier or excipient.

100. A compound of formula (V):



(V)

or a pharmaceutically acceptable salts thereof, wherein:

Ar_2 is



;

R_1 is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $C(halo)_3$, $-CH(halo)_2$, or

$-CH_2(halo)$;

each R_2 is independently:

(a) -halo,-CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-$

C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_6 is independently -(C_1–C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -$C(halo)_3$, -$CH(halo)_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -$C(halo)_3$, -$CH(halo)_2$, -CH_2(halo);

each R_8 is independently -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -(C_3–C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -$C(halo)_3$, -$CH(halo)_2$, or CH_2(halo);

each R_9 is independently -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -$C(halo)_3$, -$CH(halo)_2$, or CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_{11} is independently -CN, -OH, -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;
m is 0 or 1;
o is an integer ranging from 0 to 4;
q is an integer ranging from 0 to 6;
r is an integer ranging from 0 to 5;
s is an integer ranging from 0 to 4; and
t is an integer ranging from 0 to 2.

101. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99 and a pharmaceutically acceptable carrier or excipient.

102. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99.

103. A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99.

104. A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99.

105. A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99.

106. A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99.

107. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 99.

108. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 99.

109. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 99.

110. A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 99.

111. A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 99 and a pharmaceutically acceptable carrier or excipient.

112. The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is -halo; and

R_4 is phenyl.

113. The compound of claim 112, wherein the R_4 phenyl is unsubstituted.

114. The compound of claim 112, wherein the R_4 phenyl is substituted at the 4-position.

115. The compound of claim 114, wherein the R_4 phenyl is substituted with a -$(C_1$-$C_6)$ alkyl group.

116. The compound of claim 115, wherein the -$(C_1$-$C_6)$ alkyl group is a *tert*-butyl group.

117. The compound of claim 115, wherein the -$(C_1$-$C_6)$ alkyl group is an *iso*-propyl group.

118. The compound of claim 114, wherein the phenyl is substituted with a $-CF_3$ group.

119. The compound of claim 114, wherein the phenyl is substituted with a $-OCF_3$ group.

120. The compound of claim 112, wherein R_1 is -Cl.

121. The compound of claim 120, wherein the R_4 phenyl is unsubstituted.

122. The compound of claim 120, wherein the R_4 phenyl is substituted at the 4-position.

123. The compound of claim 122, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

124. The compound of claim 123, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

125. The compound of claim 123, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

126. The compound of claim 122, wherein the phenyl is substituted with a -CF_3 group.

127. The compound of claim 122, wherein the phenyl is substituted with a -OCF_3 group.

128. The compound of claim 112, wherein R_1 is -F.

129. The compound of claim 128, wherein the R_4 phenyl is unsubstituted.

130. The compound of claim 128, wherein the R_4 phenyl is substituted at the 4-position.

131. The compound of claim 130, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

132. The compound of claim 131, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

133. The compound of claim 131, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

134. The compound of claim 130, wherein the phenyl is substituted with a -CF_3 group.

135. The compound of claim 130, wherein the phenyl is substituted with a -OCF_3 group.

136. The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is $-CH_3$; and

R_4 is phenyl.

137. The compound of claim 136, wherein the R_4 phenyl is unsubstituted.

138. The compound of claim 136, wherein the R_4 phenyl is substituted at the 4-position.

139. The compound of claim 138, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

140. The compound of claim 139, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

141. The compound of claim 139, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

142. The compound of claim 138, wherein the phenyl is substituted with a $-CF_3$ group.

143. The compound of claim 138, wherein the phenyl is substituted with a $-OCF_3$ group.

144. The compound of claim 21, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is -halo; and

R_4 is phenyl.

145. The compound of claim 144, wherein the R_4 phenyl is unsubstituted.

146. The compound of claim 144, wherein the R_4 phenyl is substituted at the 4-position.

147. The compound of claim 146, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

148. The compound of claim 147, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

149. The compound of claim 147, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

150. The compound of claim 146, wherein the phenyl is substituted with a -CF_3 group.

151. The compound of claim 146, wherein the phenyl is substituted with a -OCF_3 group.

152. The compound of claim 144, wherein R_1 is -Cl.

153. The compound of claim 152, wherein the R_4 phenyl is unsubstituted.

154. The compound of claim 152, wherein the R_4 phenyl is substituted at the 4-position.

155. The compound of claim 154, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

156. The compound of claim 155, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

157. The compound of claim 155, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

158. The compound of claim 154, wherein the phenyl is substituted with a -CF_3 group.

159. The compound of claim 154, wherein the phenyl is substituted with a -OCF_3 group.

160. The compound of claim 144, wherein R_1 is -F.

161. The compound of claim 160, wherein the R_4 phenyl is unsubstituted.

162. The compound of claim 160, wherein the R_4 phenyl is substituted at the 4-position.

163. The compound of claim 162, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

164. The compound of claim 163, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

165. The compound of claim 163, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

166. The compound of claim 162, wherein the phenyl is substituted with a -CF_3 group.

167. The compound of claim 162, wherein the phenyl is substituted with a -OCF_3 group.

168. The compound of claim 21, wherein:

n is 0;

m is 1;

R_1 is -CH_3; and

R_4 is phenyl.

169. The compound of claim 168, wherein the R_4 phenyl is unsubstituted.

170. The compound of claim 168, wherein the R_4 phenyl is substituted at the 4-position.

171. The compound of claim 170, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

172. The compound of claim 171, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

173. The compound of claim 171, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

174. The compound of claim 170, wherein the phenyl is substituted with a $-CF_3$ group.

175. The compound of claim 170, wherein the phenyl is substituted with a $-OCF_3$ group.

176. The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is -halo; and

R_4 is phenyl.

177. The compound of claim 176, wherein the R_4 phenyl is unsubstituted.

178. The compound of claim 176, wherein the R_4 phenyl is substituted at the 4-position.

179. The compound of claim 178, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

180. The compound of claim 179, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

181. The compound of claim 179, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

182. The compound of claim 178, wherein the phenyl is substituted with a $-CF_3$ group.

183. The compound of claim 178, wherein the phenyl is substituted with a $-OCF_3$ group.

184. The compound of claim 176, wherein R_1 is -Cl.

185. The compound of claim 184, wherein the R_4 phenyl is unsubstituted.

186. The compound of claim 184, wherein the R_4 phenyl is substituted at the 4-position.

187. The compound of claim 186, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

188. The compound of claim 187, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

189. The compound of claim 187, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

190. The compound of claim 186, wherein the phenyl is substituted with a -CF_3 group.

191. The compound of claim 186, wherein the phenyl is substituted with a -OCF_3 group.

192. The compound of claim 176, wherein R_1 is -F.

193. The compound of claim 192, wherein the R_4 phenyl is unsubstituted.

194. The compound of claim 192, wherein the R_4 phenyl is substituted at the 4-position.

195. The compound of claim 194, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

196. The compound of claim 195, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

197. The compound of claim 195, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

198. The compound of claim 194, wherein the phenyl is substituted with a -CF_3 group.

199. The compound of claim 194, wherein the phenyl is substituted with a -OCF_3 group.

200. The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is $-CH_3$;

R_1 is $-CH_3$; and

R_4 is phenyl.

201. The compound of claim 200, wherein the R_4 phenyl is unsubstituted.

202. The compound of claim 200, wherein the R_4 phenyl is substituted at the 4-position.

203. The compound of claim 202, wherein the R_4 phenyl is substituted with a -(C_1-C_6) alkyl group.

204. The compound of claim 203, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

205. The compound of claim 203, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

206. The compound of claim 202, wherein the phenyl is substituted with a $-CF_3$ group.

207. The compound of claim 202, wherein the phenyl is substituted with a $-OCF_3$ group.